Skip to main content
. 2021 Mar 12;11(3):504. doi: 10.3390/diagnostics11030504

Figure 2.

Figure 2

Treatment response to peptide receptor radionuclide therapy (PRRT) in a patient with low systemic inflammation at baseline. Maximum-intensity-projection (MIP) image (A) and transversal PET/CT images (B–D) of baseline [68Ga]Ga-DOTA-TATE PET/CT showing osseous, hepatic, and lymph node metastases in a 66-years-old male gastro-entero-pancreatic neuroendocrine tumor (GEP-NET) patient. MIP image (E) and transversal PET/CT images (F–H) at follow-up after two cycles of PRRT demonstrating decreasing tracer uptake or disappearance of lesions (SSR-TV decreased from 496 cm3 to 277 cm3, consistent with stable disease). The baseline CRP level was 1.6 mg/L, ANC was 4.0 × 109/L, the PCM was 227.2, and the HSPI was 0, evidencing low systemic inflammation.